Generex signs S Africa Oral-lyn distribution deal

Canada's Generex Biotechnology Corp has entered into an exclusive product licensing and distribution agreement with Adcock Ingram and Adcock Ingram Healthcare for the marketing, distribution and sale of Generex Oral-lyn, the former's proprietary oral insulin spray product, in South Africa and six neighboring countries: Lesotho, Swaziland, Botswana, Namibia, Mozambique and Zimbabwe.

Adcock Ingram, part of the Tiger Brands Group, is a leading South African pharmaceutical company with an 11.4% share of the private health care market. Generex noted that the firm has an extensive range of prescription, generic and over-the-counter products and also provides life-saving hospital equipment and diagnostic products and services.

According to the latest edition of the Diabetes Atlas 2007, the prevalence of diabetes in South Africa is 4.5% while 8% of the population suffers from impaired glucose tolerance. The prevalence of diabetes in each of the other countries is: Lesotho, 4%; Swaziland, 3.8%; Botswana, 4.2%; Namibia, 4%; Mozambique, 3.1%; and Zimbabwe, 3.6%.